Consolidated Balance Sheets - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 7,203,376	$ 5,420,708
Contracts and grants receivable	841,368	1,018,835
Research and development incentives receivable	415,932	444,043
Income tax receivable	836,893
Prepaid expenses and other current assets	271,879	609,739
Total current assets	9,569,448	7,493,325
Security deposit	22,757	22,757
Office furniture and equipment, net	38,123	36,093
Deferred issuance costs	21,894	39,324
Intangible assets, net	12,908	19,699
Right-of-use lease assets	90,821	125,412
Research and development incentives receivable	56,850
Other assets	34,873	38,750
Total assets	9,847,674	7,775,360
Current liabilities:
Accounts payable	2,870,672	2,735,442
Accrued expenses	3,326,356	3,157,386
Accrued compensation	43,690	298,173
Lease liabilities - current	88,180	121,075
Total current liabilities	6,328,898	6,312,076
Non-current liabilities:
Lease liabilities, net of current	4,150	6,149
Total liabilities	6,333,048	6,318,225
Commitments and contingencies
Shareholders' equity:
Preferred stock, 350,000 shares authorized; none issued or outstanding
Common stock, $.001 par value; 50,000,000 shares authorized; 25,778,431 shares and 1,753,124 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively	25,778	21,753
Additional paid-in capital	186,624,561	177,006,004
Accumulated other comprehensive loss	(28,767)	(45,010)
Accumulated deficit	(183,106,946)	(175,525,612)
Total shareholders' equity	3,514,626	1,457,135
Total liabilities and shareholders' equity	$ 9,847,674	$ 7,775,360